Aspira Women’s Health (NASDAQ:AWH) Upgraded to “Hold” by StockNews.com

StockNews.com upgraded shares of Aspira Women’s Health (NASDAQ:AWH) from a sell rating to a hold rating in a report released on Tuesday morning.

Separately, Alliance Global Partners reduced their target price on shares of Aspira Women’s Health from $7.00 to $5.50 and set a buy rating on the stock in a report on Wednesday, August 14th.

Aspira Women’s Health Stock Up 1.0 %

Aspira Women’s Health stock opened at $1.08 on Tuesday. Aspira Women’s Health has a 52 week low of $0.86 and a 52 week high of $6.75. The firm’s 50-day simple moving average is $1.34 and its 200 day simple moving average is $2.65. The firm has a market capitalization of $13.45 million, a PE ratio of -0.74 and a beta of 1.54.

Aspira Women’s Health (NASDAQ:AWH) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. The business had revenue of $2.42 million during the quarter, compared to analysts’ expectations of $2.60 million. During the same quarter in the prior year, the firm earned ($0.28) earnings per share. On average, research analysts expect that Aspira Women’s Health will post -1.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. raised its position in Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 179,371 shares of the company’s stock after purchasing an additional 53,997 shares during the period. B. Riley Wealth Advisors Inc. owned about 1.73% of Aspira Women’s Health worth $732,000 at the end of the most recent reporting period. 12.19% of the stock is owned by institutional investors and hedge funds.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.